GBIO vs KRYS vs ARWR vs RCKT

For growth investors, Arrowhead Pharmaceuticals, Inc.

(ARWR) is the stronger pick with 232. 6% revenue growth year-over-year, versus 33. 9% for Krystal Biotech, Inc. (KRYS). Krystal Biotech, Inc. (KRYS) offers the better valuation at 44. 7x trailing P/E (39. 4x forward), making it the more compelling value choice. Analysts rate Krystal Biotech, Inc. (KRYS) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Krystal Biotech, Inc.

(KRYS) delivered a total return of +364. 0%, compared to -98. 2% for Generation Bio Co. (GBIO). Over 10 years, the gap is even starker: KRYS returned +27. 7% versus GBIO's -97. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Krystal Biotech, Inc.

(KRYS) is the lower-risk stock at 1. 02β versus Arrowhead Pharmaceuticals, Inc. 's 1. 74β — meaning ARWR is approximately 70% more volatile than KRYS relative to the S&P 500. On balance sheet safety, Krystal Biotech, Inc. (KRYS) carries a lower debt/equity ratio of 1% versus 109% for Generation Bio Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arrowhead Pharmaceuticals, Inc.

(ARWR) is pulling ahead at 232. 6% versus 33. 9% for Krystal Biotech, Inc. (KRYS). On earnings-per-share growth, the picture is similar: Krystal Biotech, Inc. grew EPS 128. 0% year-over-year, compared to -0. 7% for Generation Bio Co.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Krystal Biotech, Inc.

(KRYS) is the more profitable company, earning 52. 6% net margin versus -661. 9% for Generation Bio Co. — meaning it keeps 52. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KRYS leads at 41. 5% versus -715. 8% for GBIO. At the gross margin level — before operating expenses — GBIO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RCKT: 37.

7% to $5. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Arrowhead Pharmaceuticals, Inc.

(ARWR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+1162% 10Y return). Generation Bio Co. (GBIO) carries a higher beta of 1. 66 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ARWR: +1162%, GBIO: -97. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GBIO is a small-cap high-growth stock; KRYS is a small-cap high-growth stock; ARWR is a mid-cap high-growth stock; RCKT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.